Trial reportInternational journal of dermatology2014
Scabies community prevalence and mass drug administration in two Fijian villages.
Trial report in International journal of dermatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 4 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- Prevalence and determinants of scabies: A global systematic review and meta-analysis.Tropical medicine & international health : TM & IH · 2024Pooled it
- A systematic review of scabies transmission models and data to evaluate the cost-effectiveness of scabies interventions.PLoS neglected tropical diseases · 2019Pooled it
- Treatment, prevention and public health management of impetigo, scabies, crusted scabies and fungal skin infections in endemic populations: a systematic review.Tropical medicine & international health : TM & IH · 2019Pooled it
- Interventions for preventing the spread of infestation in close contacts of people with scabies.The Cochrane database of systematic reviews · 2014Pooled it
- Feasibility and safety of mass drug coadministration with azithromycin and ivermectin for the control of neglected tropical diseases: a single-arm intervention trial.The Lancet. Global health · 2018Trial
- Tracing the Itch: A Spatiotemporal Analysis of Scabies Rates and Its Risk Factors Using the Global Burden of Disease 2021 Data.Tropical medicine & international health : TM & IH · 2025Article
- Prevalence of scabies and community knowledge, attitudes, and practices on the disease in the middle belt of Ghana.BMC public health · 2025Article
- Burden of scabies and bacterial skin infection in Kiribati: results of a national population-based survey 2023.The Lancet regional health. Western Pacific · 2025Article
- An outbreak of scabies in a fishing community in Hoima District, Uganda, February - June, 2022.BMC infectious diseases · 2025Article
- Burden of scabies in a Ghanaian penitentiary.PloS one · 2024Article
- Living in a large family and low daily water consumption substantially expose for human scabies in rural Ethiopia: a matched analysis.Journal of health, population, and nutrition · 2023Article
- Can ivermectin mass drug administrations to control scabies also reduce skin and soft tissue infections? Hospitalizations and primary care presentations lower after a large-scale trial in Fiji.The Lancet regional health. Western Pacific · 2022Article
- Mass drug administration for endemic scabies: a systematic review.Tropical diseases, travel medicine and vaccines · 2021Review
- Scabies and impetigo in Samoa: A school-based clinical and molecular epidemiological study.The Lancet regional health. Western Pacific · 2021Article
- Population pharmacokinetics of ivermectin for the treatment of scabies in Indigenous Australian children.PLoS neglected tropical diseases · 2020Article
- A scabies outbreak in the North East Region of Ghana: The necessity for prompt intervention.PLoS neglected tropical diseases · 2020Article
- Scabies outbreak investigation and risk factors in Kechabira district, Southern Ethiopia: unmatched case control study.BMC research notes · 2019Article
- Impact of ivermectin administered for scabies treatment on the prevalence of head lice in Atoifi, Solomon Islands.PLoS neglected tropical diseases · 2018Article
- The Epidemiology of Scabies and Impetigo in Relation to Demographic and Residential Characteristics: Baseline Findings from the Skin Health Intervention Fiji Trial.The American journal of tropical medicine and hygiene · 2017Article
- Protocol for the systematic review of the prevention, treatment and public health management of impetigo, scabies and fungal skin infections in resource-limited settings.Systematic reviews · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundScabies has been estimated to affect approximately 300 million people worldwide each year. Scabies rates are high and pose a significant public health problem in Fiji. Community-based comparison treatment trials have not been undertaken. We estimated scabies prevalence and compared the efficacy and tolerability of mass drug administration (MDA) of benzyl benzoate lotion (BB) or oral ivermectin (IVM) in two villages in Fiji.
methodsA prospective MDA trial was undertaken in two Fijian villages, comparing three daily applications of BB with single dose IVM or permethrin cream for those aged under two years. The therapies were offered to all community members regardless of the presence of scabies or its symptoms. The difference in prevalence was measured before and after the intervention and absolute risk reduction (ARR) and relative risk (RR) calculated.
resultsIn the BB group, there were 572 eligible participants, of whom 435 (76%) enrolled and 201 (46%) returned for follow-up. In the IVM group, there were 667 eligible participants, of whom 325 (49%) enrolled and 126 (39%) returned. Scabies prevalence was lower after the intervention in both groups. It fell from 37.9 to 20.0% (ARR 18.0%; RR 0.52) in the BB group and from 23.7 to 9.5% (ARR 14.2%; RR 0.40) in the IVM group.
conclusionsOur study provides proof of principle that MDA for scabies can reduce scabies prevalence at the community level, and that there was no significant difference in this trial between BB and oral IVM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.